Rhythm Pharmaceuticals, Inc.
Boston, MA
- UEI
- G9KGU2YDQNU4
- CAGE
- 70V50
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 222 Berkeley St #1200, Boston, MA 02116, USA
- Website
- rhythmtx.com
- Founded
- 2008
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of prader-willi syndrome | FDA Office of Acquisition and Grant Services | $999,353 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Acer Therapeutics Inc. | Boston, MA | 456110 Pharmacies and Drug Retailers |
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Astellas Pharma US, Inc. | Northbrook, IL | 325412 Pharmaceutical Preparation Manufacturing |
| Astor Drugs | Holtsville, NY | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Rhythm Pharmaceuticals, Inc., doing business as Rhythm, is a for-profit pharmaceutical company that provides drugs and pharmaceutical products to federal government agencies. Rhythm is registered in SAM.gov as an active corporate entity through September 2024.
Rhythm holds multiple federal contract indefinite delivery vehicles (IDVs) to provide pharmaceutical products under GSA Schedule 61IB for Pharmaceuticals and Drugs. This includes a $250,000 multiple award federal supply schedule contract with the Department of Veterans Affairs, lasting through October 2026. Rhythm also holds two single award blanket purchase agreements with the VA's National Acquisition Center to facilitate orders for Imicivree, a medication that treats obesity and hyperphagia caused by Prader-Willi syndrome. The first BPA has a potential value of $375,000 and lasts through November 2024. The second BPA had a potential value of $375,000 for the base year plus four option years, with ordering ending in November 2021. No set-asides were applied to Rhythm's federal awards.
Quick answers
Is Rhythm Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Rhythm Pharmaceuticals, Inc.'s SAM.gov registration is active through May 7, 2027.
Which contract vehicles does Rhythm Pharmaceuticals, Inc. hold?
Rhythm Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Rhythm Pharmaceuticals, Inc.'s most recent federal award?
Rhythm Pharmaceuticals, Inc.'s most recent federal grant award is Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of prader-willi syndrome (R01FD005094), from FDA Office of Acquisition and Grant Services, on July 10, 2015.
On GovTribe
See Rhythm Pharmaceuticals, Inc.'s full federal record
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors